Kyle Carver, M.B.A., C.P.A.

Kyle Carver serves as Chief Financial Officer of Evommune. Prior to Evommune, Kyle served as Chief Accounting Officer at Kadmon, a Sanofi Company, where he oversaw all aspects of financial and accounting operations, including Kadmon’s transition to a public company in its 2016 initial public offering through the approval and commercialization of REZUROCK® (belumosudil) in 2021. Kyle drove significant improvement in accounting operations and internal controls, helped raise more than $500 million through follow-on and convertible note offerings, and contributed to deal-making activities, including the acquisition of Kadmon by Sanofi for $1.9 billion in November 2021. Prior to Kadmon, Kyle held a senior role at KPMG, serving a broad base of life science clients. Kyle earned an MBA from the Stern School of Business at New York University and a BS in accounting from Villanova University. He is a Certified Public Accountant.